1st Conference on Clinical Trials on Alzheimer's Disease

Montpellier and Toulouse EADC Centres

Lou Ruvo Brain Institute

In collaboration with the French Federation of Memory Centres for Resource and Research

Montpellier School of Medicine

17-18-19 September 2008

Dear Colleague,

It is a great pleasure for us to invite you to attend the 1st conference Clinical Trials on Alzheimer’s Disease (CTAD), which will take place in Montpellier on 17th - 19th September, 2008.

This conference is jointly organized by the Montpellier, Toulouse European Alzheimer’s Disease Consortium (EADC) Centres and the Lou Ruvo Brain Institute.

The aims of the meeting are to bring together the current leaders in clinical trials in Alzheimer’s Disease to discuss new results, drugs in development, and future methodological issues (disease modifying, outcomes, biomarkers, health economics).

Furthermore, a Clinical Trials Training Workshop will be organized on September 17th before the Conference. This will be a high-level training course designed for investigators and clinical research assistants involved in clinical trials.

We look forward to seeing you in Montpellier,

Jacques TOUCHON   Zaven KHACHATURIAN   Bruno VELLAS

Chair CTAD Montpellier 08
CONTENTS

Program .......................................................... 4
  • Wednesday, September 17th ...................................... 4
  • Thursday, September 18th ........................................... 6
  • Friday, September 19th ............................................. 9

Poster session ..................................................... 13

General Information ............................................... 18
**15:00 INTRODUCTION**
J. TOUCHON, B. VELLAS, Z. KACHATURIAN

**BIOMARKERS ON CLINICAL TRIALS IN ALZHEIMER’S DISEASE**
Chairmen: GB. FRISONI (Brescia), MW. WEINER (San Francisco)

**ORAL COMMUNICATIONS**

**15:30 01 INTEREST OF CSF ABETA/TAU INDEX IN ALZHEIMER’S POSITIVE DIAGNOSIS**
A. GABELLE (1,2)*, S. ROCHE (1,3)*, C. GÉNY (2), F. PORTET (2,4), J. TOUCHON (2,4), S. LEHMANN (1,3)
* The first two authors contributed equally to this work
(1) CNRS, Institut de Génétique Humaine UPR 1142, Montpellier, France (2) Service de Neurologie, CHU Gui de Chauliac, Montpellier, France (3) Laboratoire de Biochimie, CHU Saint Eloi, Montpellier, France (4) Faculté de Médecine, Montpellier, France

**15:45 02 A MIXTURE MODELING APPROACH TO BIOMARKER ASSESSMENT REVEALS AN ALZHEIMER’S DISEASE SIGNATURE IN MORE THAN A THIRD OF COGNITIVELY NORMAL ELDERLY PEOPLE**
G. DE MEYER (1)*, F. SHAPIRO (1), H. VANDERSTICHELE (1), E. VANMECHELEN (1), S. ENGELBORGS (2), PP DE DEYN (2), L. SHAW (3), J. TROJANOWSKI (3) AND THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (4)
(1) Innogenetics NV, Gent, Belgium; (2) Department of Pathology and Laboratory Medicine, Institute on Aging, Alzheimer’s Disease Center, University of Pennsylvania School of Medicine, Philadelphia PA, USA; (4) Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. As such, ADNI investigators (www.loni.ucla.edu/adni/collaboration/adni_authorship_list.pdf) contributed to the design and implementation and/or provided data but did not participate in analysis or writing of this report.

**16:00 03 RATE OF VENTRICULAR ENLARGEMENT: A COMPARISON BETWEEN MEASURES DERIVED FROM 3.0 TESLA AND 1.5 TESLA MRI IN SUBJECTS PARTICIPATING IN ADNI**
S.M. NESTOR (1), R. RUP Singh (1,2), M. BORRIE (3,6), M. SMITH (6), J.L. WELLS (3,6), R. BARTHA (1,2,4,5)
(1) Centre for Functional and Metabolic Mapping, Robarts Research Institute, London, Canada; The Departments of (2) Medical Biophysics, (3) Medicine, (4) Diagnostic Radiology and Nuclear Medicine, and (5) Psychiatry, University of Western Ontario, London, Canada; (6) Division of Aging, Rehabilitation, and Geriatric Care, Lawson Health Research Institute, London, Canada

**16:15 04 EVOLUTION IN Aß40 LEVELS AND Aß42/Aß40 RATIO IN PLASMA IN RELATION TO THE DEVELOPMENT OF ALZHEIMER’S DISEASE: A MULTI-CENTER ASSESSMENT**
K. BLENNOW (3)*, G. DE MEYER (1)*, O. HANSSON (2), L. MINTHON (2), H. ZETTERBERG (3), P. LEWEZUK (4), H. VANDERTICHELE (1), E. VANMECHELEN (1), J. KORNHUBER (4), J. WILTFANG (5) (1) Innogenetics, Gent, Belgium, (2) Neuropsychiatric Clinic, Malmö University Hospital, Sweden, (3) Sahlgrenska University Hospital, Göteborg University, Sweden, (4) Department of Psychiatry, Universitätsklinikum Erlangen, (5) University of Erlangen-Nuremberg, Erlangen, Germany, (6) Kliniken/Institut der Universität Duisburg-Essen, Essen, Germany. * These authors contributed equally to this study

16:30 - 17:00 Coffee break and Poster Session
BIOMARKERS ON CLINICAL TRIALS IN ALZHEIMER’S DISEASE

LECTURES

17:00 1 Use of biomarkers for Clinical Trials in Alzheimer’s disease
Kaj BLENNNOW (Mölndal)

17:30 2 Neuro imaging outcomes in Clinical Trials in Alzheimer’s disease
Giovanni FRISONI (Brescia)

18:00 3 What can we learn from ADNI for Clinical Trials?
Michael WEINER (San Fransisco)

18:30 COMPETITIVENESS CLUSTERS
Status of projects in Alzheimer’s Disease.
J.Berthe*, J.Touchon** and projects partners.
* Orpheme Biocluster, sanofi-aventis, Montpellier - ** U888 INSERM, CHU Montpellier

19:30 Welcome Reception
METHODOLOGICAL ISSUES

Chairmen: L. SCHNEIDER (Los Angeles), H. FELDMAN (Vancouver)

ORAL COMMUNICATIONS

05 CRITICAL EVALUATION OF SELF-RATED QUALITY OF LIFE IN AD
H.J. GERTZ, M. BERWIG, H. LEICHT
Memory Clinic, Department of Psychiatry, University Clinic, Leipzig

06 BRIDGING FROM CLINICAL ENDPOINTS TO ESTIMATES OF TREATMENT VALUE FOR EXTERNAL DECISION MAKERS
C.W. ZHU (1,2), C. LEIBMAN (3), R. TOWNSEND (3), T. MCLAUGHLIN (3), N. SCARMEAS (4,5), M. ALBERT (6), J. BRANDT (6), D. BLACKER (7), M. SANO (1,8), Y. STERN (4,5)
This work is from the Geriatric Research, Education, and Clinical Center (GRECC) and Program of Research on Serious Physical and Mental Illness, Targeted Research Enhancement Program (TREP), (1) James J. Peters VA Medical Center, Bronx NY USA; (2) Brookdale Department of Geriatrics, Mount Sinai School of Medicine, New York, NY USA; (3) Elan Pharmaceuticals, Inc., South San Francisco, CA USA; (4) Cognitive Neuroscience Division of the Taub Institute for Research in Alzheimer's Disease and the Aging Brain; (5) Gertrude H. Sergievsky Center and the Department of Neurology, Columbia University Medical Center, New York, NY USA; (6) Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD USA; (7) Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA; and (8) Department of Psychiatry, Mount Sinai School of Medicine, New York, NY USA.

07 INVOLVING PATIENTS WITH ALZHEIMER’S DISEASE IN CLINICAL TRIALS: A COMPARATIVE STUDY OF ETHICS COMMITTEES FROM FRANCE AND QUEBEC
G. BRAVO (1), M.F. DUBOIS (1), S. HANSEL (2), A.M. DUGUET (3)
(1) Sherbrooke University Institute of Geriatrics, Sherbrooke, Canada; (2) Conférence Nationale des CPP, Paris, France; (3) INSERM Unité 558, Université Paul Sabatier, Toulouse, France

08 NON-PHARMACOLOGICAL TRIALS FOR BPSD IN NURSING HOME PATIENTS WITH ALZHEIMER’S DISEASE
P.H. ROBERT (1), A. DEUDON (1), N. AKE (2), X. GERVAIS (2), E. LEONE (1), B. LAVALLART (3)
(1) Centre Mémoire de Ressources et de Recherche, CHU de Nice – UNSA; (2) FFAMCO-Fédération Française des Médecins Coordonnateurs d’EHPAD; (3) DGS – Direction Générale de la Santé, France

LECTURES

9:00 L4 Interest of NTB as a cognitive outcome for therapeutic trials
Michael GRUNDMANN (San Diego)

9:30 L5 Clinical design and outcomes for symptomatic trials
Lutz FROELICH (Mannheim)
METHODOLOGICAL ISSUES

10:45 L6 The Measurement of Cognitive Change in Clinical Trials: Theory, Methodological Problems and Solutions
Paul MARUFF (Melbourne)

11:15 L7 The Measurement of Cognitive Change in Clinical Trials: Encouraging Case Studies with a New statistical Approach
Peter SNYDER (Providence)

11:45 L8 Selection of efficacy outcomes in disease-modifying trials that are meaningful to clinicians, patients and payers
Serge GAUTHIER (Montréal)

12:15 L9 Use of new criteria for clinical trials
Bruno DUBOIS (Paris)

12:45 – 14:30 Lunch Time

Chairmen: L. FROELICH (Mannheim), Ph. ROBERT (Nice)

14:30 L10 New design for large clinical trials in vascular dementia prevention
Jean-Marc ORGOGOZO (Bordeaux)

15:00 L11 Clinical trial for behavioural disorders in dementia
Lon SCHNEIDER (Los Angeles)

15:30 L12 Special problems for prevention trials: Challenges and Barriers
Zaven S. KHACHATURIAN (Las Vegas)

16:00 – 16:30 Coffee Break and Poster Session
UPDATE ON CLINICAL TRIALS

Chairmen: JM. ORGOGOZO (Bordeaux) – M. GRUNDMANN (San Diego)

16:30 SYNAPSE FORMATION IS ENHANCED BY ORAL ADMINISTRATION OF URIDINE AND DHA, THE CIRCULATING PRECURSORS OF BRAIN PHOSPHATIDES
R.J. WURTMAN, Massachusetts Institute of Technology, Cambridge, MA, USA 02139

16:50 BUTYRYLCHOLINESTERASE AND DISEASE PROGRESSION IN MILD COGNITIVE IMPAIRMENT AND EARLY ALZHEIMER’S DISEASE
Howard FELDMAN, University of British Columbia Hospital, Vancouver, British Columbia, Canada

17:10 CHALLENGES IN THE CONDUCT OF DISEASE-MODIFYING TRIALS IN AD: PRACTICAL EXPERIENCE FROM A PHASE 2 TRIAL OF TAU AGGREGATION INHIBITOR THERAPY
Claude WISCHIK, University of Aberdeen, Aberdeen (UK)
PREVENTIVE AND DISEASE MODIFYING TRIALS
Chairmen: Y. STERN (New York), Z. KHACHATURIAN (Las Vegas)

ORAL COMMUNICATIONS

8:00 010 MAPT: MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL. STUDY DESIGN
S. GILLETTE (1,3), G. ABELLAN VAN KAN (1), I. CARRIE (1), M.E. SOTO (1), J. GARDETTE (2), C. PRZYBYLSKI (2), S. ANDRIEU (1,3,4), AND B. VELLAS (1,3) FOR THE MAPT STUDY INVESTIGATORS
(1) Gérontopôle, Department of Geriatric Medicine, CHU Toulouse, F-31059, France; (2) Institute de Recherche Pierre Fabre; (3) Inserm U-558, University Toulouse III, F-31073, France; (4) Department of Epidemiology and Public Health, University III, F-31073, France

8:15 011 FISH CONSUMPTION AND COGNITIVE FUNCTION AMONG OLDER PEOPLE IN THE UK: ANALYSIS OF BASELINE DATA FROM THE OPAL STUDY
A.D. DANGOUR (1)*, E. ALLEN (1), D. ELBOURNE (1), A. FLETCHER (1), M. RICHARDS (2), R. UAUY (1)
(1) Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine; (2) Department of Epidemiology and Public Health, University College London; *Presenting author: Nutrition and Public Health Intervention Research Unit, Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom

LECTURES

8:30 L13 Can we increase cognitive reserve to treat or prevent Alzheimer’s disease?
Yaakov STERN (New York)

9:00 L14 Is MCI a good target for prevention trials?
Jacques TOUCHON (Montpellier)

9:30 L15 An update on Disease Modifying Trials
Bruno VELLAS (Toulouse)

10:00 - 10:30 Coffee break and Poster Session
## NEW THERAPIES

*Chairmen: L. SCHNEIDER (Los Angeles), P. AISEN (San Diego)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td><strong>L16</strong> Results of the LEADe study</td>
<td>Howard FELDMAN (Vancouver)</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>L17</strong> New therapy with stem cells</td>
<td>Bengt WINBLAD (Stockholm), Roxana NAT (Stockholm)</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>L18</strong> Gamma secretase inhibitor clinical research</td>
<td>Eric SIEMERS (Philadelphia)</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>L19</strong> New and future therapies for Alzheimer’s disease</td>
<td>Ezio GIACOBINI (Geneva)</td>
</tr>
<tr>
<td>12:30</td>
<td><strong>L20</strong> Results of the US Phase II Trial of Huperzine A in Mild to Moderate Alzheimer’s disease</td>
<td>Paul AISEN (San Diego)</td>
</tr>
</tbody>
</table>

*Lunch time*

13:00 - 14:00
**ORAL COMMUNICATIONS**

**14:00 014** A COMBINATION OF GALANTAMINE PLUS MEMANTINE IN AMCI EXERTS POSITIVE COGNITIVE EFFECTS MOST PRONOUNCED IN PRESUMED PREDEMENTIA AD  
O. PETERS (1), D. LORENZ (1), H.J. MÖLLER (2), L. FRÖLICH (3), I. HEUSER (1)  
(1) Department of Psychiatry and Psychotherapy, Charité-CBF, Berlin, Germany; (2) Department of Psychiatry and Psychotherapy, LMU Munich, Munich, Germany; (3) CIMH Mannheim, University of Heidelberg, Mannheim, Germany

**14:15 015** PHASE I STUDY OF THE 18F-LABELLED BENZOTHIAZOLE DERIVATIVE [18F]AH110690 AS AN IN VIVO BIOMARKER OF AD-RELATED BRAIN AMYLOIDOSIS  
R VANDENBERGHE (1), L THURFJELL (2), R OWENIUS (2), DJ BROOKS (2), N NELISSEN (1), M KOOLE (3), G BORMANS (3), K VAN LAERE (3)  
(1) Neurology and (3) Nuclear Medicine Department, University Hospitals Leuven & K.U.Leuven, Leuven, Belgium; (2) GE Healthcare, Medical Diagnostics, Research and Development, Amersham, United Kingdom / Uppsala, Sweden

**14:30 016** PROOF OF CONCEPT STUDY OF PLASMA EXCHANGE WITH 5% HUMAN ALBUMIN GRIFOLS® IN THE TREATMENT OF PATIENTS WITH MILD ALZHEIMER’S DISEASE  
(1) ACE Foundation, Catalan Institute of Applied Neurosciences, Barcelona; (2) Neurology Service, University General Hospital Vall d’Hebron, Barcelona; (3) Blood and Tissue Bank, University General Hospital Vall d’Hebron, Barcelona; (4) Alzheimer’s Disease Research Centre, University of Pittsburgh, (5) Grifols Institute, Barcelona; (6) Neuropathology Institute, University General Hospital Bellvitge, Barcelona, Spain

**14:45** Coffee break and Poster session
NETWORK IN ALZHEIMER’S DISEASE
Symposium of the German Competence network on dementias (CND)

Chairs: Eckart RUETHER, Lutz FROELICH

15:15  S1 Structure and scope of the CND
       Wolfgang MAIER (Bonn)

15:35  S2 Studies on early and differential diagnosis of Alzheimer’s disease
       Johannes KORNHUBER (Nuremberg), Jens WILTFANG (Duisburg)

16:00  S3 Multi-center MR spectroscopy for predictive dementia diagnosis
       Frank JESSEN (Bonn)

16:20  S4 Clinical trials on combination therapy in Alzheimer’s disease and MCI
       Isabella HEUSER (Berlin), Lutz FROELICH (Mannheim)

16:45  Summary and clinical conclusions
       Eckart RUETHER (Munich)
POSTER SESSION

P1 THE INFLUENCE OF MATRIX TYPE, DIURNAL RHYTHM AND SAMPLE COLLECTION AND PROCESSING ON THE MEASUREMENT OF PLASMA β-AMYLOID ISOFORMS USING THE “INNO-BIA PLASMA A FORMS” Multiplex ASSAY
(1) Innogenetics NV, Gent, Belgium; (2) BARC-CRI laboratories, Gent, Belgium; (3) Eli Lilly and Company, Indianapolis, IN, USA; (4) Windlesham, Surrey, GU20 6PH, United Kingdom

P2 GAB2 GENE DOES NOT MODIFY ALZHEIMER’S RISK IN SPANISH APOE E4 CARRIERS.
(1) Department of Structural Genomics, NeoCodex, Sevilla; (2) ACE Foundation, Catalán Institute of Applied Neurosciences; (3) Neurology Service, University General Hospital Vall d’Hebron, Barcelona; (4) Geriatric Hospital of Cantoblanco, Madrid; (5) University Hospital Virgen de la Arrixaca, Murcia, Spain

P3 COMMUNICATING WITH THE OLDER PERSON / DECISIONMAKING AND INFORMED CONSENT (FRAILTY, DEMENTIA).
L. HUGONOT-DIENER (1)*, J. EL BCHIRI (1), M.L. FRAISSE (2), F. VON RAISON (2), M. BONE (3), E. DURON (1), J.M. HUSSON (4)
(1) France; (2) Switzerland; (3) United Kingdom; (4) Belgium; * MEDFORMA B. 79 108 bis Bd A. Blanqui 75013 Paris, France

P4 COST-EFFECTIVENESS OF POST-DIAGNOSIS TREATMENT IN DEMENTIA COORDINATED BY MULTIDISCIPLINARY MEMORY CLINICS IN COMPARISON TO TREATMENT COORDINATED BY GENERAL PRACTITIONERS: THE DESIGN OF THE AD-EURO STUDY
E.J. MEEUWSEN (1), R.J.F. MELIS (1), E.M. ADANG (2), P.F. KRABBE (2), C.J.M. SCHOLZEL-DORENBOS (1,3), M.G.M. OLDE RIKKERT (1)
(1) Radboud University Nijmegen Medical Centre, Department of Geriatrics, (2) Radboud University Nijmegen Medical Centre, Department of Epidemiology, Biostatistics and Hta, (3) Memory Clinic Slingeland Hospital Doetinchem, The Netherlands

P5 THE BENEFITS OF REGULAR MEDICAL MONITORING IN DEMENTIA CLINICAL TRIALS
M SMITH (1,2), J TRUEMNER (1), S BEST (1), M LOZANSKI (1), C NSIAH (1), J WELLS (1,2,3), M BORRIE (1,2,3)
(1) Geriatric Clinical Trials Group, Parkwood Hospital, (2) Lawson Health Research Institute, (3) University of Western Ontario, London, Ontario, Canada

P6 RAPIDLY PROGRESSIVE ALZHEIMER’S DISEASE
C. SCHMIDT, K. REDYK, B. MEISSNER, I. ZERR
Department of Neurology, University of Goettingen, Germany

P7 BEYOND FACTOR ANALYSIS: ANALYTIC METHODS FOR FACTORS, DIMENSIONS, AND ENDPOINTS IN CLINICAL TRIALS FOR ALZHEIMER’S DISEASE
R.E. TRACTENBERG
Departments of Neurology, Biostatistics, Bioinformatics & Biomathematics, and Psychiatry; Georgetown University School of Medicine, Washington DC, USA
POSTER SESSION

P8 LATENT VARIABLE MODELING IN CLINICAL TRIALS ON ALZHEIMER’S DISEASE
R.E. TRACTENBERG
Departments of Neurology, Biostatistics, Bioinformatics & Biomathematics, and Psychiatry; Georgetown University School of Medicine, Washington DC, USA

P9 A TWO-YEAR OPEN-LABEL CLINICAL TRIAL OF GALANTAMINE THERAPY IN CHINESE ALZHEIMER’S DISEASE PATIENTS IN HONG KONG
LW. CHU, P.Y. YIK, W. MOK, C.P. CHUNG
Division of Geriatrics, Department of Medicine Queen Mary Hospital The University of Hong Kong 102 Pokfulam Road Hong Kong SAR China

P10 EFFECT OF XALIPRODEN, A COMPOUND WITH NEUROTROPHIC PROPERTIES, ON THE PROGRESSION OF ALZHEIMER’S DISEASE (AD). RESULTS OF TWO LARGE 18-MONTH STUDIES ASSESSING CLINICAL EFFICACY AND CEREBRAL ATROPHY.
S. GAUTHIER (1), P. DOUILLET (2), R. DOODY (3), N.C. FOX (4) AND J.-M. ORGOGOZO (5), FOR THE XALIPRODEN AD STUDY TEAM
(1) McGill Centre for Studies in Aging, Quebec, Canada; (2) Sanofi-aventis, Montpellier, France; (3) Baylor College of Medicine, Houston, Texas, USA; (4) Institute of Neurology, London, United Kingdom; (5) CHU Pellegrin, Bordeaux, France

P11 NORMAL TRANSTHYRETIN - RETINOL PLASMA LEVELS ATTENUATE THE CEREBRAL LESIONS OF ALZHEIMER’S PATIENTS
Y. INGENBLEEK (1), J. BIENVENU (2)
(1) Laboratory of Nutrition, University Louis Pasteur, Strasbourg 1, France; (2) Laboratory of Immunology, University Claude Bernard, Lyon 1, France

P12 DOXYCYCLINE AND RIFAMPIN FOR TREATMENT OF ALZHEIMER’S DISEASE: A MULTI-CENTRED RANDOMIZED CONTROLLED TRIAL
D.W. MOLLOY, T. STANDISH, D. COWAN, E. ALMEIDA, P. DILORETO
McMaster University/St. Peter’s Hospital, Hamilton, Canada

P13 CLINICAL TRIALS IN DEMENTIA FOR APPROVED AND NOVEL COMPOUNDS: WHICH ONES COULD CS5R AND CS5R SITES ATTRACT FOR OUR PATIENTS?
S. WOOLMORE-GOODWIN (1, 4), J. CLARKE (3), P. BERARDI (7), J. WELLS (1,2,3,4,5,6), M. SMITH (2,4,5,6), T. PURCELL (6), M. BORRIE (1,2,3,4,5,6)
(1) St. Joseph’s Health Care London, (2) Lawson Health Research Institute, (3) University of Western Ontario, (4) Aging Rehabilitation and Geriatric Care, (5) Geriatric Clinical Trials Group, (6) Consortium of Canadian Centres for Clinical Cognitive Research (7), Northern Ontario School of Medicine. Ontario, Canada

P14 CLINICAL TRIALS IN DEMENTIA: POPULATIONS SERVED BY CONSORTIUM OF CANADIAN CENTRES FOR CLINICAL COGNITIVE RESEARCH (CS5R) SITES
S. WOOLMORE-GOODWIN (1), I. GUTMANIS (1,4), T. PURCELL (3), M. BORRIE (1,2,3,4)
(1) St. Joseph’s Health Care, London, ON, (2) Geriatric Medicine, University of Western Ontario, (3) Consortium of Canadian Centre for Clinical Cognitive Research, (4) Division of Aging, Rehabilitation and Geriatric Care, Canada

P15 MEASUREMENT OF BEHAVIOURAL SYMPTOMS AND RESPONSE TO TREATMENT IN CLINICAL TRIALS
PH. ROBERT (1), E. REYNISH (2), C. CANTET (3), B. VELLAS (2),
(1) Centre Mémoire de Ressources et de Recherche, CHU de Nice – Inserm JE 2441 – UNSA; (2) Inserm, U558, F-31073, Toulouse, France; University Toulouse III, Toulouse, F-31073, France; Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, F-31059, France; (3) Department of Epidemiology and Public Health, Toulouse University Hospital Toulouse, F-31073, France
**POSTER SESSION**

**P16** MEMANTINE DISCONTINUATION IN NURSING HOME RESIDENTS WITH ALZHEIMER’S DISEASE WAS ASSOCIATED WITH A DECLINING HEALTH STATUS: A FACTOR ANALYSIS


(1) Forest Research Institute, Jersey City, NJ, USA; (2) Institute for the Study of Aging, New York, NY, USA; (3) AMF Consulting, Los Angeles, CA, USA; (4) Johns Hopkins Bayview Medical Center, Baltimore, MD, USA

**P17** MODULATORY EFFECT OF LMN ANTI-OXIDANT DIET IN THE ADULT MOUSE BRAIN NEUROGENESIS.

M. UNZETA (1), T. VALENTE (1), J. HIDALGO (1), B. RAMIREZ (2), N. ANGLÉS (2), J.R. REGUANT (2), M. BOADA (3)

(1) Universitat Autonoma de Barcelona, Bellaterra, Barcelona, Spain; (2) La Morella Nuts SA, Reus, Tarragona, Spain; (3) Fundació ACE. Institut Catalá de Neurociències Aplicades, Barcelona, Spain

**P18** CEREBROVASCULAR AND AUTONOMIC DYSFUNCTION IN ALZHEIMER’S DISEASE

J.A. CLAASSEN, A.H. VAN BEEK, M.G. OLDE RIKKERT

Department Of Geriatric Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

**P19** PROOF OF CONCEPT STUDY OF PLASMA EXCHANGE WITH 5% HUMAN ALBUMIN GRIFOLS® IN THE TREATMENT OF PATIENTS WITH MILD ALZHEIMER’S DISEASE: FUNCTIONAL IMAGING (SPECT) FINDINGS.


**P20** INVESTIGATING THE ENHANCING EFFECT OF MUSIC THERAPY ON ABILITIES TO RECALL AUTOBIOGRAPHICAL MEMORIES IN ALZHEIMER’S DISEASE

C. LATGER (1), E. TRAMONI (2), C. ELKHOURY (1), S. AUBERT-KHALIFA (3), M. CECCALDI (1,2)

(1) Service de Neurologie et de Neuropsychologie, CHU Timone, Marseille, France; (2) Laboratoire Epilepsies et Cognition, INSERM U 751, Faculté de Médecine, Marseille; (3) INCM, CNRS UMR 6193, Université de la Méditerranée, Marseille, France

**P21** DEVELOPMENT OF AFFITOPE VACCINES FOR ALZHEIMER’S DISEASE (AD) – FROM CONCEPT TO CLINICAL TESTING

A. SCHNEEBERGER, M. MANDLER, O. OTAVA, F. MATTNER, W. SCHMIDT

AFFIRIS GmbH, Vienna, Austria.

**P22** INFLUENCE OF TEMPORAL PROCESSING IN LEXICAL PERFORMANCE EVOLUTION OF PATIENTS WITH ALZHEIMER’S DISEASE

P. GATIGNOL (1,2), C. DAVID (2), C. GUITTON (2), M. PLAZA (1)

(1) Laboratoire de Psychologie et Neurosciences cognitives, UMR CNRS 8189, Université Paris Descartes, 71 avenue Edouard-Vaillant. 92774 Boulogne Billancourt, France; (2) ENT and Otoneurosurgery department; Hôpital Pitié Salpêtrière, 47/83 Boulevard de l’Hôpital 75013 Paris, France
POSTER SESSION

P23 NEW INSIGHT INTO CLINICAL TRIAL ON PROLINE RICH POLYPEPTIDES IN AD – TRANSCRIPTOMAL NETWORK ANALYSIS
P. SZANISZLO (1), P. GERMAN (1), G. HAJAS (1), M. KRUZEL (2), I. BOLDOGH (1)
(1) Department of Microbiology and Immunology, UTMB Galveston, Texas, USA; (2) PharmaReview Corporation, Houston, Texas, USA

P24 IDENTIFYING COGNITIVE ENHANCEMENT IN MAN I: ADDING TESTING TO ROUTINE PHASE I TRIALS
K. WESNES, S. SATEK, P. TURK
Cognitive Drug Research Ltd, Goring-on-Thames, United Kingdom

P25 IDENTIFYING COGNITIVE ENHANCEMENT IN MAN II: MODELS AND PHARMACODYNAMIC TRIALS IN VOLUNTEERS
S. SATEK, K. WESNES, P. TURK
Cognitive Drug Research Ltd, Goring-on-Thames, United Kingdom

P26 IDENTIFYING COGNITIVE ENHANCEMENT IN MAN III: INDETIFYING EFFICACY IN THE DEMENTIAS
P. TURK, K. WESNES, S. SATEK, M. VINAY
Cognitive Drug Research Ltd, Goring-on-Thames, United Kingdom

P27 INFLUENCE OF GOLM1 POLYMORPHISMS ON PROGRESSION OF ALZHEIMER’S DISEASE
S. WETTEN (1), H. LI (2), N. GALWEY (1), R.A. GIBSON (1), M.C. IRIZARRY (2)
(1) Genetics, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW UK; (2) WW Epidemiology, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina, 27709, USA

P28 A TWO-YEAR RANDOMIZED TRIAL OF THE IMPACT OF A SPECIFIC CARE PLAN IN 1121 AD PATIENTS (PLASA STUDY): PRELIMINARY RESULTS
F. NOURHASHEMI (1,2), S. GILLETTE-GUYONNET (1,2), S. ANDRIEU (2,3), Y. ROLLAND (1,2), P.J. OUSSET (1,2), B. VELLAS (1,2), AND THE PLASA GROUP
(1) CHU Toulouse, F631059 Toulouse, France ; (2) Inserm US88, F-31073 Toulouse, France ; (3) CHU Toulouse, Service d’épidémiologie et de santé publique, F-31073 Toulouse, France

P29 A WORLD WIDE MULTICENTER COMPARISON OF ASSAYS FOR AD CSF BIOMARKERS
N.A. VERWEY (1), K. BLENNOW (2), C. CLARK (3), G.M. COLE (4), P.P. DE DEYN (5), D. GALASKO (6), H. HAMPEL (7), T. HARTMANN (8), E. KAPAKI (9), L. LANNFELT (10), P.D. MEHTA (11), L. PARNETTI (12), A. PETZOLD (13), T. PIRTTILA (14), L. SALEH (15), A. SKINNINGSRUD (16), J.C.V. SWIETEN (17), M.M. VERBEEK (18), J. WILTFANG (19), S. YOUNKIN (20) AND M.A. BLANKENSTEIN (1)
(1) Departments Clinical Chemistry and Neurology, VUMC, Amsterdam, The Netherlands; (2) Neurochemistry lab, Mölndal hospital, Mölndal, Sweden; (3) The Penn Ralston Center, University of Pennsylvania, Philadelphia, USA; (4) UCLA School of Nursing, Los Angeles, USA; (5) Institutu Bor-Bunge, University of Antwerp, Antwerp, Belgium; (6) Department of Biochemical Research, University of San Diego, La Jolla, USA; (7) Psychiatriche ik der LMU, Munich, Germany; (8) Molecular Biology, University of Heidelberg, Heidelberg, Germany; (9) Department of Neurology, Eginition Hospital, Athens, Greece; (10) Institutionen för folkhalsa och vardnetnkap, Rudbecklab, Uppsala, Sweden; (11) Institute for basic research in development disabilities, New York, USA; (12) Department of Neurology, Ospedale S.M. della Misericordia, Perugia, Italy; (13) Institute of Neurology, Clinical Neurosciences, UCL, London, United Kingdom; (14) Department of Neurology, University of Kuopio, Kuopio, Finland; (15) Department of Clinical Chemistry, University Hospital of Basel, Basel, Switzerland; (16) Department of Clinical Chemistry, Akershus University Hospital, Lørenskog, Norway; (17) Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands; (18) Laboratory of Neurology, Radboud University, Nijmegen, The Netherlands; (19) Neurobiology Laboratory, University of Erlangen-Neurenberg, Erlangen, Germany; (20) Mayo Clinic, Jacksonville, USA
**POSTER SESSION**

**P30 USE OF AN US CLAIMS DATABASE AND AN US ALZHEIMER’S DISEASE REGISTRY TO ASSESS CLINICAL TRIAL ELIGIBILITY CRITERIA**
L. ISHIHARA-PAUL (1), A. VIWANATHAN (2), J.K. ALLEN (1), B.T. HYMAN (1), R. BETENSKY (2), J. WEIL (1), D. BLACKER (2), M.C. IRIZARRY (1)
(1) WW Epidemiology, GlaxoSmithKline, Research Triangle Park, US and Harlow, UK; (2) Massachusetts Alzheimer’s Disease Research Center, Massachusetts General Hospital, Boston, MA.

**P31 NEUROPSYCHOLOGICAL CLUSTERS OF COGNITIVE IMPAIRMENT - WHICH CLUSTER BEARS THE HIGHEST RISK OF CONVERTING TO DEMENTIA?**
M. DAMIAN (1), P.J. VISSER (2), L. FRÖLICH (1)
(1) Division of Geriatric Psychiatry and Memory Clinic, Central Institute of Mental Health, Faculty of Clinical Medicine Mannheim, University of Heidelberg; (2) Department of Psychiatry and Neuropsychology, University of Maastricht, The Netherlands; Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands

**P32 DOES SEROTONIN AUGMENTATION HAVE ANY EFFET ON COGNITION AND ACTIVITIES OF DAILY LIVING IN ALZHEIMER’S DEMENTIA? A DOUBLE-BLIND PLACEBO-CONTROL CLINICAL TRIAL**
A. MOWLA (1), M. MOSAVINASAB (1), A. BORHANIHAGHIHGI (2), H. HAGHSHENAS (1)
(1) Department of Psychiatry, Shiraz University of Medical Sciences, Shiraz, Iran; (2) Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.

**P33 IS DONEPEZIL MORE THAN SYMPTOMATIC? THE HIPPOCAMPAL STUDY**
B DUBOIS (1), M SARAZIN (1), S LEHERICY (3), M CHUPIN (2), J TONELLI (4), L GARNERO (2), D DORMONT (2) AND “DONEPEZIL HIPPOCAMPUS STUDY GROUP”
(1) INSERM-UPMC UMRs610, Federation of Neurology, APHP, Salpetrière Hospital, Univ Paris6, Paris, France; (2) Cognitive Neuroscience and Brain Imaging Laboratory, CNRS UPR6410, Paris, France; (3) INSERM U610 unit, Paris, France and CENIR, Neuro-imaging Unit, Hôpital de la Salpêtrière, Paris, France; (4) Eisai SAS, Paris, France

**P34 DIFFERENTIAL PROCESSING OF APP IN SKIN FIBROBLASTS OF PATIENTS WITH ALZHEIMER’S DISEASE IS ASSOCIATED WITH MODULATION IN LIPID MEMBRANE STATUS**
C MALAPLATE-ARMAND (1,2), C DESBENE (1,2), MC ESCANYÉ (1), T. PILLOT (2), JL. OLIVIER (1,2)
(1) Laboratoire de biochimie spécialisée – biologie moléculaire, CHU de Nancy
(2) JE Lipidomix, INPL Nancy

**P35 MEMANTINE TREATMENT WITH ALZHEIMER’S DISEASE IS ASSOCIATED WITH A SLOWER RIGHT HIPPOCAMPAL VOLUME LOSS: AN OPEN-LABEL, MULTI-CENTER TRIAL**
M.WEINER(1),S.M. GRAHAM (2), R.K. HOFBAUER (2), S.Y. YU (2), S. LI (2), H. HSU (2), JOYCE SUHY (3), J.L. PERHACH (2)
(1) University of California San Francisco, San Francisco, CA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Synarc, San Francisco, CA, USA

**P36 The GUIDAGE STUDY - Evolution of cognitive function assessments after one year of follow up: A 5 year Double Blind, Randomized Trial of the efficacy of Egb761 for the prevention of Alzheimer’s disease in patients over 70 with a memory complaint.**
COLEY N, OUSSET PJ, ANDRIEU S, MATHIEUX-FORTUNET H, GARNIER P, VELLAS B, AND GUIDAGE GROUP.
**GENERAL INFORMATION**

**Congress venue**
The Medical School is a 15 minute walk from the Place de la Comedie.

Address:
2, rue Ecole de Médecine
34000 Montpellier
France

**Congress secretariat**
AMS - 11 boulevard Henri IV
34000 Montpellier
04.67.61.94.14
mail@ams.fr

---

**Registration**

**Registration fee**

<table>
<thead>
<tr>
<th>Registration fee (1*)</th>
<th>After 06/21/2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>600,00 €</td>
<td></td>
</tr>
</tbody>
</table>

Thursday Lunch : 25 €     Friday Lunch : 25 €

(1*) Registration fee includes:
- admission to all scientific sessions
- a nametag
- a congress bag with program and JNHA review
- coffee breaks
- welcome reception
- one year JNHA free subscription

**FMC (French accreditation)**

Agreement N° FMC: **100 224**
This training course belongs to the 1st Category of mandatory training courses according to the French law of July 13th 2006 for valid mandatory ongoing medical training.

For each half-day course **4 credits** will be validated.
2nd Conference
Clinical Trials
on Alzheimer’s Disease

Toulouse 2009
http://www.ctad.fr

Montpellier and Toulouse EADC Centres
Lou Ruvo Brain Institute

In collaboration with the French Federation of Memory Centres for Resource and Research

Hôtel-Dieu Saint Jacques
16-17-18 September 2009
Clinical Trials on Alzheimer's Disease

On line Congress


Major Sponsors

Eisai
Pfizer
IPSEN
JANSSEN-CILAG
Lilly
Lundbeck
NOVARTIS
Sanofi Aventis